Form 4: Atara Biotherapeutics Director Matthew K Fust Reports Acquisition and Disposal of Common Stock

Director Matthew K Fust reports acquiring 150,000 shares of Atara Biotherapeutics common stock and disposing of an unspecified amount.

Summary

• On March 31, 2024, Matthew K Fust, a director of Atara Biotherapeutics, Inc., reported a transaction involving the company's common stock.
• Fust acquired 150,000 shares of common stock.
• The acquisition was made at a price of $0.
• Fust also disposed of an unspecified amount of common stock.
• Following the reported transactions, Fust beneficially owns 259,000 shares of Atara Biotherapeutics common stock.
• The acquired restricted stock units will vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The acquisition of shares is a positive sign, but the disposal of an unspecified amount introduces uncertainty. The overall impact is likely minimal.

Positives

• The acquisition of 150,000 shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Negatives

• The disposal of an unspecified amount of shares by the director could be interpreted negatively, although the reason for disposal is not provided.

Risks

• The Form 4 filing itself doesn't inherently present risks, but the disposal of shares could raise questions about the director's sentiment regarding the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon the director's continuous service through the date of the Issuer's annual meeting of stockholders for the calendar year 2025.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
• The information provided in this filing is consistent with the level of detail typically found in similar filings from other biotech companies such as Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• Shareholders may interpret the director's stock transactions as a signal of confidence or concern, potentially influencing their investment decisions.

Key Dates